Literature DB >> 42458

Presynaptic alpha-adrenoceptor blocking properties among tri- and tetra-cyclic antidepressant drugs.

B Harper, I E Hughes.   

Abstract

1 The effect of various antidepressants (5 x 10(-8) to 2 x 10(-5) M) on the resting overflow of tritium, on the evoked overflow and the contractile response to electrical stimulation (2.5 Hz, 2.0 ms) has been determined in mouse vas deferens previously incubated with [(3)H]-(-)-noradrenaline.2 Mianserin and ORG GC 94 produced a concentration-dependent increase of more than two fold in the electrically evoked overflow and the contractile response and, at the highest concentration, slightly increased resting release. These effects were largely unchanged in the presence of a concentration of cocaine effective in blocking noradrenaline uptake (1.1 x 10(-5) M).3 The ability of phentolamine (1 x 10(-5) M) to increase both the evoked overflow of tritium and the contractile response was greatly reduced when these parameters were already elevated by the presence of mianserin or ORG GC 94.4 The inhibitory effect of exogenous (-)-noradrenaline on evoked overflow was greatly reduced in the presence of mianserin or ORG GC 94 (4 x 10(-6) M).5 The inhibitory effect of clonidine on the twitch response of the mouse vas deferens was antagonized by mianserin and ORG GC 94 in a competitive manner (pA(2) values 7.3 and 7.1 respectively).6 Maprotiline, desipramine and nortriptyline (> 3 x 10(-6) M) produced a parallel fall in both evoked tritium overflow and in the contractile response and increased the resting overflow at higher concentrations. These effects were largely unchanged in the presence of cocaine (1.1 x 10(-5) M).7 Doxepin, imipramine and iprindole all increased resting overflow at high concentrations (2 x 10(-5) M) but produced only small changes in evoked overflow and in the contractile response at lower concentrations.8 It is concluded that mianserin and ORG GC 94 produce a blockade of presynaptic alpha-adrenoceptors which could contribute to an antidepressant effect but that this type of action is not common to all antidepressants.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 42458      PMCID: PMC2043908          DOI: 10.1111/j.1476-5381.1979.tb08696.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  13 in total

Review 1.  Regulation of noradrenaline release by presynaptic receptor systems.

Authors:  K Starke
Journal:  Rev Physiol Biochem Pharmacol       Date:  1977       Impact factor: 5.545

2.  Arrhythmias and inhibition of noradrenaline uptake caused by tricyclic antidepressants and chlorpromazine on the isolated perfused rabbit heart.

Authors:  N Barth; M Manns; E Muscholl
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1975       Impact factor: 3.000

3.  Blockade of presynaptic alpha-receptors and of amine uptake in the rat brain by the antidepressant mianserine.

Authors:  P A Baumann; L Maître
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1977-10       Impact factor: 3.000

4.  Presynaptic alpha-adrenoceptors and [3H]-noradrenaline overflow from the mouse was deferens [proceedings].

Authors:  I Marshall; P A Nasmyth; N B Shepperson
Journal:  Br J Pharmacol       Date:  1978-03       Impact factor: 8.739

Review 5.  Sixth gaddum memorial lecture, National Institute for Medical Research, Mill Hill, January 1977. Presynaptic receptors and their role in the regulation of transmitter release.

Authors:  S Z Langer
Journal:  Br J Pharmacol       Date:  1977-08       Impact factor: 8.739

6.  Effect of iprindole on amine uptake in man.

Authors:  W E Fann; J M Davis; D S Janowsky; J S Kaufmann; J D Griffith; J A Oates
Journal:  Arch Gen Psychiatry       Date:  1972-02

7.  The use of desipramine in studies of noradrenergic nerve function.

Authors:  I E Hughes; B Kneen; V A Main
Journal:  J Pharm Pharmacol       Date:  1974-11       Impact factor: 3.765

8.  Some quantitative uses of drug antagonists.

Authors:  O ARUNLAKSHANA; H O SCHILD
Journal:  Br J Pharmacol Chemother       Date:  1959-03

9.  Noradrenaline, depressive illness, and the action of amitriptyline.

Authors:  K Ghose; A Coppen
Journal:  Psychopharmacology (Berl)       Date:  1977-08-31       Impact factor: 4.530

10.  Autonomic actions and interactions of mianserin hydrochloride (Org. GB 94) and amitriptyline in patients with depressive illness.

Authors:  K Ghose; A Coppen; P Turner
Journal:  Psychopharmacology (Berl)       Date:  1976-09-17       Impact factor: 4.530

View more
  6 in total

1.  Chronic inhibition of monoamine oxidase reduces noradrenaline release in rat vas deferens and anococcygeus muscle.

Authors:  D Hovevey-Sion; J P Finberg
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-07       Impact factor: 3.000

2.  Reduced peripheral presynaptic adrenoceptor sensitivity following chronic antidepressant treatment in rats.

Authors:  J P Finberg; A Tal
Journal:  Br J Pharmacol       Date:  1985-03       Impact factor: 8.739

3.  Differences in presynaptic alpha-blockade, noradrenaline uptake inhibition, and potential antidepressant activity between (+)- and (-)mianserin.

Authors:  H Schoemaker; H H Berendsen; H J Stevens; V J Nickolson
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

4.  Anxiolytics antagonize yohimbine's discriminative stimulus properties.

Authors:  R G Browne
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

5.  Effect of destruction of central noradrenergic and serotonergic nerve terminals by systemic neurotoxins on the long-term effects of antidepressants on beta-adrenoceptors and 5-HT2 binding sites in the rat cerebral cortex.

Authors:  H Hall; S B Ross; M Sällemark
Journal:  J Neural Transm       Date:  1984       Impact factor: 3.575

6.  Interaction between mianserin and clonidine at alpha 2-adrenoceptors.

Authors:  Y Pommier; M Andréjak; P Mouillé; H Dabiré; B Lucet; H Schmitt
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1982-03       Impact factor: 3.000

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.